Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07063745 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
A Phase 2 study of Metastatic Non-small Cell Lung Cancer With MTAP Deletion, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 590
- Enrollment target
- 20
- Study locations
NCT07063745 is a Phase 2 study of Metastatic Non-small Cell Lung Cancer With MTAP Deletion that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 590 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT07063745, a Phase 2 study of Metastatic Non-small Cell Lung Cancer With MTAP Deletion, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 590 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- OTHER Placebo
- DRUG BMS-986504
Study Locations (20)
Florida
- Local Institution - 0152 - Fort Lauderdale
- Mayo Clinic in Florida - Jacksonville
- Local Institution - 0430 - St. Petersburg
Michigan
- Local Institution - 0418 - Ann Arbor
- Local Institution - 0405 - Detroit
- Local Institution - 0420 - Traverse City
Arizona
- Mayo Clinic in Arizona - Phoenix - Phoenix
- Local Institution - 0120 - Tucson
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Local Institution - 0444 - Los Angeles
Kentucky
- Baptist Health Lexington - Lexington
- University of Kentucky Chandler Medical Center - Lexington
Alaska
- Alaska Oncology and Hematology - Anchorage
Arkansas
- Highlands Oncology Group - Springdale
Idaho
- St. Luke's Cancer Institute: Boise - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2031-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07063745
The ClinicalTrials.gov registry entry for NCT07063745 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 590 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Non-small Cell Lung Cancer With MTAP Deletion appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT07063745 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT07063745 about?
NCT07063745 is a clinical study titled "A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion". The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with ...
What is the current status of trial NCT07063745?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 590 participants. The study started on 2026-01-02. Estimated completion is 2031-08-12.
What conditions does trial NCT07063745 study?
This clinical trial studies the following conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion.
What interventions are being tested in trial NCT07063745?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Placebo (OTHER), BMS-986504 (DRUG).
Who is sponsoring clinical trial NCT07063745?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07063745 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.